Last reviewed · How we verify

NCT03372434

Clinical Investigation of the Next-Generation Intraocular Lenses

Completed NA Results posted Last updated 24 June 2025
What this trial tests

NA trial testing Investigational Intraocular Lens Device #1: Model ZFR00 in Cataract in 225 participants. Completed in 30 October 2018.

Timeline
16 January 2018
Primary endpoint
11 July 2018
30 October 2018

Quick facts

Lead sponsorAbbott Medical Optics
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment225
Start date16 January 2018
Primary completion11 July 2018
Estimated completion30 October 2018
Sites12 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Abbott Medical Optics

Who can join

22 and older, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Distance Corrected Intermediate Visual Acuity Primary · 1 month

Visual Acuity (VA) was assessed monocularly (each eye separately) under photopic (well-lit) conditions using best distance correction (distance refraction) and high contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart at 66 cm from spectacle plane. It was measured in logarithm of the minimum angle of resolution (logMAR), on an ETDRS chart. A lower numeric value represented better VA. This analysis was pre-specified for the first operative eye only.

GroupValue95% CI
Model ZFR000.098± 0.115
Model ZLB000.219± 0.146
Model ZYR000.147± 0.149

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Model ZFR00
Serious: 5/78 (6%)
Deaths: 0/78
Model ZLB00
Serious: 13/73 (18%)
Deaths: 0/73
Model ZYR00
Serious: 4/74 (5%)
Deaths: 0/74

Serious adverse events (16 terms)

ReactionSystemModel ZFR00Model ZLB00Model ZYR00
HospitalizationGeneral disorders
Cystoid Macular EdemaEye disorders
Macular HoleEye disorders
Bothersome Visual SymptomProduct Issues
Herpes Zoster KeratitisEye disorders
Retinal DetachmentEye disorders
Visual symptoms requiring secondary surgical interventionProduct Issues
Haptic anterior to capsule bagEye disorders
Increase in cells likely due to non-compliance with ocular medication regimenEye disorders
Retinal HoleEye disorders
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)
Patent Foramen OvaleCardiac disorders
AngioplastyCardiac disorders
B-cell LymphomaBlood and lymphatic system disorders
ShinglesInfections and infestations
Undisclosed illness requiring Hospice careGeneral disorders
Other adverse events (1 terms — click to expand)

ReactionSystemModel ZFR00Model ZLB00Model ZYR00
Bothersome visual symptomProduct Issues

Most-reported serious reactions: Hospitalization, Cystoid Macular Edema, Macular Hole, Bothersome Visual Symptom, Herpes Zoster Keratitis, Retinal Detachment, Visual symptoms requiring secondary surgical intervention, Haptic anterior to capsule bag.

Data from ClinicalTrials.gov NCT03372434 adverse events section.

Sponsor's own description

This study is a 6-month, prospective, multicenter, subject/evaluator-masked, bilateral, randomized clinical investigation of the TECNIS Next-Generation Model ZFR00 and Model ZYR00 IOLs versus the TECNIS Multifocal Model ZLB00 control IOL. The study will be conducted at up to 14 sites in the U.S.A and will enroll up to 260 subjects to achieve approximately 220 randomized and bilaterally-implanted subjects, resulting in approximately 195 evaluable subjects (65 in each test group and 65 in the control group) at 1 and 6 months. Subjects are to be implanted with the same IOL in both eyes, the ZFR00 IOL, the ZYR00 IOL or the ZLB00 control IOL. The eye implanted first will be considered the primary study eye.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cataract

Currently open trials in the same condition.

Other Abbott Medical Optics trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03372434.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing